The goal of this clinical trial is to determine the pharmacokinetics (how the body interacts with administered substances for the entire duration of exposure) of Gen-1124 in an oral formulation (taken by mouth) in healthy volunteers. It will also learn about the safety of Gen-1124. The main questions it aims to answer are: \- How does Gen-1124 interact with a human body? Researchers will look at how Gen-1124 interacts with the body and what side effects it may cause. Participants will: * Take Gen-1124 for a single dose * Remain in clinic for 2 days for checkups and tests * Recieve a phone call for a checkup 3 and 7 days after the single dose
Age range
18 Years – 55 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
PK Endpoints - Plasma levels
Timeframe: From enrollment to Day 2 discharge
PK Endpoints - Plasma levels
Timeframe: From enrollment to Day 2 discharge
PK Endpoints - Plasma levels
Timeframe: From enrollment to Day 2 discharge
PK Endpoints - Plasma levels
Timeframe: From enrollment to Day 2 discharge
PK Endpoints - Plasma levels
Timeframe: From enrollment to Day 2 discharge
Safety Endpoints - Clinically significant changes to physical exam
Timeframe: From informed consent/screening visit to Day 2
Safety Endpoints - Clinically significant changes to ECG results
Timeframe: From informed consent/screening visit to Day 2
Safety Endpoints - Clinically significant changes to clinical lab results
Timeframe: From informed consent/screening visit to Day 2
Safety Endpoints - Clinically significant changes to vital signs
Timeframe: From informed consent/screening visit to Day 2
Safety Endpoints - Changes to concomitant medications
Timeframe: From 14 days (or 5 half-lives, whichever is longer) prior to Screening through completion of the study.